Markus Britschgi joined Roche in 2009 and since then leads the discovery and research activities around alpha-synuclein and passive immunotherapies for this target in Parkinson’s disease. In addition, he investigates the role of immune pathways in neurodegenerative diseases and explores novel translational biomarkers of Parkinson’s and Alzheimer’s disease. From 2003 to 2009, Britschgi was postdoc and instructor at Stanford University (Stanford, CA, USA) and investigated the role of immune pathways in age-related neurodegenerative disorders and also identified systemic biomarkers for normal aging and neurodegenerative diseases. Britschgi received his PhD in Immunology in 2002 from the University of Bern (Switzerland) and performed his undergraduate and master studies in biochemistry at the University of Fribourg (Switzerland) where he graduated in 1997. Britschgi is first and senior author of original research papers published in various high impact journals and has co-authored several papers and reviews as well.